Digital Monitoring for Patients Post Coronary Interventions to Reduce Risk for Recurrent Adverse Cardiovascular Events

Status: Recruiting
Location: See location...
Intervention Type: Other, Behavioral, Device
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

The study aims to support patients immediately after percutaneous coronary intervention (PCI) by implementing a telemonitoring program. Eligible patients have coronary heart disease and undergo PCI. The intervention group receives remote monitoring and text-based follow-up, with established health goals and education on using the telemonitoring application, along with necessary devices. The control group gets standard care. Outcomes measured include blood pressure, LDL levels, patient satisfaction, revascularization, and mortality. The study findings will enhance patient care after PCI and contribute evidence for widespread telemonitoring implementation in healthcare systems, aiding medical therapy and lifestyle modifications.

Eligibility
Participation Requirements
Sex: All
Healthy Volunteers: f
View:

• Includes patients with coronary heart disease diagnosis and treatment with PCI who follow up at University of California Davis Health.

Locations
United States
California
University of California, Davis Medical Center Division of Cardiovascular Medicine
RECRUITING
Sacramento
Contact Information
Primary
Surabhi Atreja, MD
smatreja@ucdavis.edu
(916) 734-2011
Backup
Lina Du, BS
Time Frame
Start Date: 2024-01-01
Estimated Completion Date: 2026-01-01
Participants
Target number of participants: 200
Treatments
Active_comparator: Discharged with LiveCare and Text Message Intervention
Patients receive blood pressure monitoring and text messages reminders for enrollment in cardiac rehab, follow up appointment, diet and exercise counseling.
Sham_comparator: Discharged with Conventional Care
Patients do not receive blood pressure monitoring and text messages reminders for enrollment in cardiac rehab, follow up appointment, diet and exercise counseling.
Sponsors
Leads: University of California, Davis

This content was sourced from clinicaltrials.gov